CYP1A1 polymorphisms and cervical cancer risk: a meta-analysis

Objective: Cytochrome P4501A1 (CYP1A1) may contribute to the development of cervical cancer through affecting the metabolism of estrogen and carcinogens. The current data of connection between the CYP1A1 polymorphisms and cervical cancer risk is not thoroughly acceptable. We conduct a meta-analysis to evaluate whether there is certain correlation between polymorphisms of CYP1A1 and cervical cancer. Materials and Methods: Some eligible case-control studies are expected to be identified from Embase, PubMed and other databases. Pooled odds ratios (ORs) and 95% CIs are calculated in a fixed-effects or random effects model as appropriate. Results: There were 13 case-control studies, including 2374 cases and 2436 controls. Overall, the pooled results showed that there was a strong connection between cervical cancer and CYP1A1 MspI polymorphism in all models: allele contrast (C vs. T) , OR=1.43.95% CI=1.11-1.83; homozygote comparison (CC vs. TT), OR=2.09. 95% CI 1.26-3.48; heterozygote comparison (CT vs. TT), OR=1.48, 95% CI=1.12-1.95; dominant model (CC+CT vs. TT), OR=1.53, 95% CI=1.11-2.10; recessive model (CC vs. CT+TT), OR=1.64, 95% CI= 1.13-2.39). There were also strong associations between cervical cancer and CYP1A1 Ile462Val polymorphism in all models except for the recessive model. Conclusion: Present meta-analyses reveal that both MspI and Ile462Val polymorphisms may be correlated with cervical cancer.